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4Abstract61
The colonisation, development and maturation of the newborn gastrointestinal62
tract that begins immediately at birth and continues for 2 years, is modulated63
by numerous factors including mode of delivery, feeding regime, maternal64
diet/weight, probiotic and prebiotic use and antibiotic exposure pre-, peri- and65
post-natally. While in the past, culture-based approaches were used to assess66
the impact of these factors on the gut microbiota, these have now largely been67
replaced by culture-independent DNA-based approaches and most recently,68
high-throughput sequencing-based forms thereof. The aim of this review is to69
summarise recent research into the modulatory factors that impact on the70
acquisition and development of the infant gut microbiota, to outline the71
knowledge recently gained through the use of culture-independent techniques72
and, in particular, highlight advances in high-throughput sequencing and how73
these technologies have, and will continue to, fill gaps in our knowledge with74
respect to the human intestinal microbiota.75
76
77
5Introduction78
Following birth, the gut microbial composition undergoes remarkable79
alterations during the first two years of life. More specifically, the human80
gastrointestinal tract (GIT) changes from being initially sterile, to possessing81
an adult-like stable microbiome by the time the infant reaches 2 years of age82
1. Despite being home to more than 1014 bacterial cells (outnumbering the83
total amount of human cells in the body (1013)) 2, which contribute up to 60%84
of faecal mass, the human gut contains a surprisingly limited number of85
dominant phyla (i.e. Firmicutes and Bacteroidetes). A diverse number of86
factors contribute to the development of the gut microbiota and impact on the87
unique composition that each individual develops (Figure 1).88
89
The infant gut is initially an aerobic environment. However, through90
colonisation the environment is altered, resulting in a reduction in oxygen91
levels thereby creating an environment suitable for the growth of anaerobes.92
The initial gut composition is simple, dynamic and very unstable and93
undergoes marked fluctuations 3. Nonetheless, evidence exists that the initial94
colonisation influences subsequent immune system development by95
influencing intestinal morphology and gut associated lymphoid tissue (GALT)96
function. Furthermore, more recently it has also been suggested that the gut97
microbiota play a significant role in the regulation of the immune system98
(something which will be returned to later) 4. Thus, an altered gut microbiota99
composition can potentially predispose the infant to more frequent infections100
and allergic disease risk 5.101
102
6Given the enormity of the bacterial population present in the gut, it has been103
proposed that the gut bacterial microbiome be considered a “super organism”104
6. While the composition of the species present within this microbiome is of105
great significance, the overall diversity of this population can also be of critical106
importance. In the majority of cases, the interaction between the bacteria and107
the human host can be regarded as mutualistic, in that both the bacteria and108
the host benefit from a mutual relationship. The vast array of functions which109
these bacteria are capable of are still being elucidated but many benefits have110
been well documented 7, and these functions can be divided into those which111
are metabolic, trophic or protective 7. The mechanisms by which these112
functions occur are outside the scope of this review, but examples of some of113
these diverse functions have been summarised in Figure 2.114
115
Advances in techniques to study gut microbiota116
In the past, investigations into the infant gut microbiome were culture-based117
and therefore the insight provided was limited by a lack of knowledge with118
respect to the growth requirements of the majority of microbes present in the119
gut. Selection of the correct media, temperature, oxygen content and time for120
growth all impacted on the ability to generate accurate culture-based results. It121
has since been estimated that as little as 10-50% of the entire gut bacteria are122
easily cultured 8. With our increasing knowledge of the growth requirements of123
a vast number of microbes, as well as the availability of specialised culturing124
media, we can now successfully culture increasing numbers of different125
microbes, as recently demonstrated by Goodman et al. 9. Culture-based126
approaches are still being employed in some studies (despite the availability127
7of much more sophisticated and complex technologies, some of which will be128
outlined below; Table 1), though most often in combination with culture-129
independent techniques such as fluorescent in situ hybridization (FISH) or130
flow cytometry. Despite these advances in culturing capabilities, this approach131
is still unsuitable for characterising the microbiota as a whole, especially in132
complex environments such as the human gut.133
Another approach that has been taken has involved the study of differences in134
the composition or presence/absence of microflora associated characteristics135
(MACs) between different subject groups. The concept of MACs was first136
proposed in 1978 10 and some examples include mucin degradation,137
conversion of cholesterol to coprostanol and inactivation of tryptic activity.138
One of the most commonly studied MACs are short chain fatty acids (SCFAs).139
These are a sub-group of fatty acids that contain 6 or less carbons on their140
aliphatic side chain. They include acetic, butyric and propionic acids and are141
produced as a result of fermentation of dietary fibre by bacteria in the large142
intestine. Differences in bacteria populations could result in alterations in the143
type and amount of faecal SCFAs present. The comparison of MACs has144
been a major component of studies investigating the contribution of the145
microbiome in, for example, coeliacs relative to controls 11, 12, probiotic or146
antibiotic treated infants/children compared to controls 13, 14 and even to147
identify changes in gut microbiota-related functionality due to allergic disease148
15, 16. While MACs are useful as a tool for screening large populations, such as149
in epidemiological studies, they are most useful when supplemented with150
detailed insights into gut microbial composition.151
152
8Due to the limitations associated with culture-based approaches, researchers153
began to develop and utilize culture-independent, DNA-based approaches to154
gain such detailed insights. There are a variety of such DNA-based155
approaches available. Among the most popular of those employed initially156
were temperature gradient gel electrophoresis (TGGE) and denaturing157
gradient gel electrophoresis (DGGE) 17. These systems work by the158
separation of amplicons (often of the 16S ribosomal RNA gene (rRNA)) based159
on their GC content, to reveal distinctive patterns. The 16S gene allows160
phylogenetic identification of the bacteria present, as this gene is present in all161
prokaryotes and contains conserved and variable regions which facilitates162
amplicon generation and differentiation 18. These techniques are rapid and163
provide an overview of the composition of microbial populations. Downstream164
analysis to identify specific components of the population can be facilitated by165
band excision and sequencing, however, despite this, these approaches166
usually only provide limited phylogenetic information and, as with all PCR167
based strategies, can be subject to PCR bias. Dot-blot hybridization168
technologies have also been utilized to investigate the infant gut microbiota 19.169
In this case, RNA is isolated, immobilised and assessed qualitatively and170
quantitatively using oligonucleotide-labelled probes. This approach is not171
subject to PCR bias, but the resolution of results can be limited, and it is172
focussed on specific populations rather than the microbiota as a whole.173
Furthermore, results depend on the ability to firstly generate reference174
sequences to facilitate the design of probes. Similarly, FISH approaches have175
been used and have also provided valuable information, but, as with dot-blot176
hybridization, the results are again focussed on specific populations and177
9reference sequence generation is again required 20, 21. Quantitative PCR178
(qPCR) is now also frequently used, which measures the accumulation of179
products through measurement of fluorescently labelled primers or probes 22.180
Studies have also employed several techniques in combination, such as dot-181
blot hybridization together with qPCR to allow for the quantification of bacterial182
numbers as well as identification of the different species present 23. Other183
studies have used qPCR and FISH in combination, yielding significantly more184
detailed and enlightening results 24.185
186
The next step in the evolution of culture-independent technologies involved187
the use of phylogenetic microarrays 3. Microarrays are similar to the188
previously described approaches, but are more advantageous in that they189
allow hybridisation of greater numbers of sequences to the one slide, thus190
allowing extensive data generation from the one read. Briefly, the sequences191
are attached to the glass slide, using a robotic arrayer. These sequences are192
fluorescently labelled and their expression can be measured using a193
fluorescence assay 25. Thus it is clear that a shift in gut microbiota research194
has occurred in recent decades, to focussing more specifically on the bacterial195
16S ribosomal RNA (rRNA) gene 26, 27.196
197
As highlighted by an extensive review in 2008 26, the investigation into the198
gastrointestinal microbiota has moved into the “metagenomic era”, with199
increasing numbers of studies employing DNA sequencing-based techniques.200
Sequencing of the 16S rRNA gene has the advantage of providing the gene201
sequence itself (and, thus, valuable information regarding the identity of202
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microbes present) rather than the indirect, and less accurate, information203
provided by DGGE and TGGE. When carried out on a larger scale, DNA204
sequencing can reveal detailed information relating to the overall microbial205
population in a particular environment e.g. the human gut which contrasts with206
targeted approaches such as dot-blotting, FISH, qPCR and, to a lesser extent,207
phylogenetic microarrays. The earliest sequencing-based approaches were208
based on cloning of full length 16S rRNA genes into a plasmid, its introduction209
into a host (most often Escherichia coli, E. coli), followed by conventional,210
capillary-based, Sanger sequencing thereof. While this technique allows the211
identification of bacterial species, it is slow and expensive. This process can212
take up to 3 weeks from the generation of purified DNA to the generation of213
results 28. Today the focus has shifted to high-throughput sequencing which,214
because of the scale at which sequence data is generated, provides a greater215
insight into the precise composition of the microbiota present 27. High-216
throughput sequencing technologies (also known as next generation217
sequencing), such as those supplied by Roche/454 and Illumina, have been218
used extensively for gut microbiota-related studies. The Roche/454219
pyrosequencing approach is based on sequencing by synthesis. For 16S220
sequencing, purified DNA is used to generate an amplicon library which then221
undergoes an emulsion based clonal PCR. This PCR uses beads coated in222
oligonucleotides, which are specific to adaptor sequences attached to the223
amplicons. Following bead recovery and enrichment, the amplicon coated224
beads are added to a picotitre plate and sequencing ensues. Sequencing225
involves an enzymatic reaction and, as each nucleotide is sequentially added,226
pyrophosphate is released and ATP is subsequently generated. This then227
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enables the conversion of luciferin and the emission and detection of photons228
of light 28. For Illumina sequencing, single stranded DNA fragments are229
generated with oligo-ligated adaptors attached. These are then attached to a230
glass flow cell, onto which oligonucleotides complementary to the adaptor231
region of the amplicons are attached. Heating and cooling cycles follow, after232
which incubation with reagents and a polymerase to hybridise the DNA233
fragments to the oligonucleotides occurs. The flow cell, when placed into a234
cassette, is then sequenced and the incorporation of the nucleotides (each of235
which is fluorescently labelled) is measured using imaging technologies 29.236
However, these techniques also have their own inherent limitations. In the237
case of amplicons, they are prone to PCR bias. One also requires extensive238
bioinformatic capabilities to handle the vast amount of bioinformatic data239
generated and the associated platforms are expensive to purchase and run. In240
addition to this, while these technologies provide valuable information with241
respect to the proportions of different populations present, qPCR is often242
required to generate absolute quantification data.243
While amplicon-based 16S compositional sequencing has been most244
frequently used for human studies, another option is shotgun sequencing245
whereby the metagenomic DNA (i.e. all of the DNA from the microbial246
population) is first fragmented into short lengths and sequenced randomly 30,247
31. This approach involves the sequencing of random fragments of DNA rather248
than specifically targeted regions and provides valuable information regarding249
the functional potential and, to some degree, the identity of the microbes250
present in a particular niche and, if carried out on a sufficiently large enough251
scale, entire genomic sequences can be generated 32, 33. As with target-252
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specific approaches, shotgun sequencing has also benefited enormously from253
the availability of high-throughput sequencing technologies 2, 34-36.254
255
Other high-throughput sequencing technologies have, or will shortly, emerge.256
Examples include the Ion torrent 37, SOLid (Applied Biosystems) 38, SMRT257
(Pacific Biosystems) 39 and nano pore sequencers 40, 41. These techniques258
aim to provide longer, or greater numbers of reads, more rapidly and/or at a259
lower cost. While the exact mechanisms, advantages, disadvantages and260
differences between these new culture-independent techniques are outside261
the scope of this review (and are covered extensively in other reviews cited262
herein), it is worth noting that these technologies will undoubtedly263
revolutionise the way in which we study the human gut microbiota in the264
future. Indeed, in the past few years alone, these high-throughput sequencing265
technologies have already been employed to study the gut microbiota266
associated with different diseases including, but not limited to, diabetes 42,267
Crohn’s disease 43, irritable bowel syndrome 44, cancer 45, 46 and obesity 34, 47,268
48 and to investigate the effects of diet 35, 49 and antibiotics 50 on the gut269
microbiota.270
271
Thus, it is clear that in the past 15 years researchers have progressed from272
relying heavily on culture-based approaches to utilizing sophisticated high-273
throughput sequencing technologies to investigate the microbial world within274
us. Before proceeding, it should also be noted that while there has been275
enormous progress made, one limitation that still remains with respect to276
studying the gut microbiota, is accessing a representative bacterial sample to277
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study. Most frequently, the composition of the gut microbiota of infants is278
assessed following the collection of stool samples and the extraction of DNA.279
However, there are limitations to this approach, as faecal samples are most280
representative of the bacteria present in the lower colon but less281
representative of the bacteria of the stomach and upper intestine. However,282
despite this limitation, faecal samples are very useful with respect to283
identifying the majority of bacteria present in the colon, which is where the284
preponderance of intestinal bacteria reside (due to transit time, pH, nutrient285
availability etc.) and, in the absence of other alternatives, faecal-based286
assessments remain the approach of choice. This review will focus on the287
infant gut microbiota development, based on results generated using culture-288
independent approaches and will highlight how the results generated using289
these different technologies compare to those generated using older290
approaches.291
292
Shaping the early intestinal microbiota: Effect of mode of delivery293
Infants undergo rapid colonisation during delivery and in the first few hours294
following birth. Initially the infant is colonised by aerobes, followed by295
facultative anaerobes and, as the oxygen level is diminished, strict anaerobes296
predominate 51-53. Some of the earliest colonisers include E. coli and297
enterococci and, once the oxygen has been consumed, they are followed by298
strict anaerobes including bifidobacteria, Bacteroides and Clostridium spp. 1,299
54. However, while these general patterns of colonisation occur, colonisation300
of the infant’s gut is altered by birth mode. Infants born vaginally are colonised301
with vaginal and faecal microbes from their mother and this has been shown302
14
to result in a strong maternal signature, which contrasts with the microbiota of303
Caesarean born infants 1. It is generally accepted that infants born by304
Caesarean section have no access to the mother’s microbiota, although there305
have been suggestions that the swallowing of amniotic fluid allows some306
colonisation of the infant’s gut in utero 55. Caesarean delivered infants are307
instead colonised by microbes from the environment, such as those from308
healthcare staff, wards and other infants. A recent study of 9 women and their309
10 infants (i.e. including one set of twins) was completed using high-310
throughput sequencing (Roche/454) of the variable 2 (V2) region of the311
bacterial 16S rRNA gene 56. The authors sequenced 34 samples from the312
mother and 46 from their infants, resulting in 157,915 partial 16S sequences.313
The study found that there was a strong vertical transmission of vaginal314
microbes from the mother to the infant when birth was by vaginal delivery,315
resulting in a dominant number of lactobacilli within hours of birth. In contrast,316
in the gut of Caesarean delivered infants there was a strong presence of317
maternal skin microbes, with staphylococci being dominant in these infants 56.318
This study advances our understanding of the relationship between the319
mother’s microbiota and that of her infant and highlights the benefits of320
employing high-throughput sequencing for such purposes.321
322
Other DNA-based studies have also been completed that support the323
aforementioned results. A study of over 1000 infants in the Netherlands324
examined, using qPCR, the potential of over 16 factors to alter the325
composition of the infant gut microbiota at age 1 month 57. When the gut326
microbiota of infants that were vaginally born was compared with those born327
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by Caesarean section, it was apparent that the latter group had 100 fold lower328
bifidobacteria and Bacteroides fragilis numbers. In addition, birth by329
Caesarean delivery was also associated with a 100 fold increased330
colonisation with Clostridium difficile. C. difficile is a Gram positive spore-331
forming anaerobic pathogen, which has been shown to be capable of332
producing toxins and is frequently a cause of diarrhoea and colitis 58-60.333
Notably, a follow-on study by the same group found a positive association334
between mode of delivery, the gut microbiota and atopy risk 61. Another such335
study focussed on the microbial composition of even younger infants (i.e. 3336
days old) (n=46) 62. The TGGE- and DGGE-based approaches employed337
again highlighted the strong impact of delivery mode on the microbial338
composition, with vaginally born, exclusively breastfed infants, having the339
highest bifidobacteria levels and lowest C. difficile counts of all infants 62.340
Surprisingly, although subject to bias and the inherent limitations outlined341
previously, culture-based approaches have revealed similar trends in that,342
when Adlerberth et al. examined over 300 infants across 3 European cohorts,343
they found that Caesarean delivered infants are colonised with greater344
numbers of clostridia and Klebsiella and decreased E. coli, bifidobacteria and345
Bacteroides compared to vaginally delivered infants 63.346
347
A FISH-based study of 168 one month old Finnish infants provided a348
somewhat different set of results in that the Clostridium, Bacteroides and349
Lactobacillus populations in the gut were found to be similar in both vaginally350
and Caesarean born infants 64. Notably, however, it was again apparent that351
bifidobacteria were greatly impacted upon by delivery mode, with a 1300 fold352
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higher level observed in infants born vaginally. This is significant as353
bifidobacteria, along with lactobacilli, are the microorganisms most frequently354
employed as probiotics. Bifidobacteria were first characterised in the period355
1899-1900 and, since then, have been shown to predominate in vaginally356
delivered, breastfed infants. The health promoting properties of specific357
lactobacilli and bifidobacteria have been reported and include the combat of358
diarrhoea, increasing resistance to pathogenic microorganisms, decreased359
occurrence of urinary, gastrointestinal and respiratory infections, alleviating360
lactose intolerance symptoms, reducing constipation and boosting immune361
functioning 65-67. However, as has been highlighted recently by EFSA362
(European Food Safety Authority), it is critical that the health claims pertaining363
to each specific strain are rigorously tested 68. Nonetheless, research to date364
does suggest that a delivery-mode mediated variation in the numbers and365
diversity of both lactobacilli and bifidobacteria occurs and considerable366
research has been carried out with a view to determining the significance of367
these differences. Moving forward this area of research will benefit from more368
detailed investigations to determine precisely which populations are369
influenced by delivery modes and to establish which of these populations can370
be specifically associated with subsequent health-related impacts.371
372
Culture-based studies have shown that the influence of delivery mode on the373
gut microbiota can persist for some time and thus may impact on the374
subsequent health of the infant 51. Recent culture-independent approaches375
have also shown this to be the case, once more showing the ability to verify376
the results of culture-based approaches using new culture-independent and377
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high-throughput sequencing based technologies. More specifically, a FISH-378
based study of 60 children at age 7 years, in which 31 had been born by379
Caesarean section and 29 vaginally 53, revealed that vaginally born infants380
had increased levels of clostridia compared to those delivered by Caesarean381
section. The authors reported that lower clostridia levels appear in those382
infants being treated for asthma at age 7, while healthy children had higher383
numbers of clostridia, thereby highlighting a potential long-term consequence384
of the impact of delivery mode on the gut microbiota. A recent birth cohort385
supports these gut microbiota findings of a long-term consequence on health386
due to delivery mode 69. The study examined the association between387
Caesarean delivery and the subsequent risk of being obese at age 23-25388
years. After controlling for sex, birth weight, activity, income, smoking and389
maternal factors (schooling and smoking during the pregnancy), it was390
revealed that those born by Caesarean section had a 58% increased risk of391
obesity compared to vaginally born infants, thus highlighting the long-term392
effects of a factor that impacts on the infant’s gut microbiota 69. This topic has393
also been the focus of a recent review 70.394
395
Effect of early feeding regime396
The impact of feeding choice, i.e. breastfeeding versus formula feeding, and397
weaning on the infant gut microbiota has also been investigated. The World398
Health Organisation (WHO) recommends exclusive breastfeeding of all infants399
up to 6 months of age and continued supplemented breastfeeding up to 12400
months of age 71. Despite this, there are large variations in the rates of401
breastfeeding from one country to another. Presently, Scandinavian countries402
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have some of the highest levels of breastfeeding with, for example, recent403
data for Norway suggesting that 96% of infants are breastfed at birth, of which404
84% are exclusively breastfed 72. In comparison to these high levels, many405
developed countries have much lower rates of breastfeeding, with recent Irish406
data suggesting that rates of exclusive breastfeeding currently stand at just407
47% at hospital discharge and drop to between 6.5 and 9.4% of women408
partially breastfeeding during the first 6 months of the infant’s life 73. In the409
USA, the 2007 National Immunisation Survey found that at 3 months of age,410
just 33% of infants were exclusively breastfed, and that this level falls further411
at 6 months to just 13% being exclusively breastfed 74.412
413
Breastfeeding is accepted as being highly beneficial to both mothers and414
infants 75. Breastmilk is a nutritious food for the newborn, the composition of415
which varies in response to the infant’s changing nutritional requirements and416
age. In addition to containing the appropriate nutrients for the growing infant,417
breastmilk can have a significant impact on the gut microbial composition by418
virtue of being a source of prebiotics (non digestible food ingredients that419
beneficially effect the host by selectively stimulating the growth of one or a420
limited number of bacteria in the colon), lactoferrin (an antimicrobial protein)421
and lysozyme (an enzyme found naturally in milk, tears and sweat that is422
capable of digesting the cell walls of bacteria) 76. Thus, the constituents of423
milk may play a determining role in the gut microbial composition and424
development. Significantly, there are considerable differences in the425
oligosaccharide composition of human breastmilk and cows’ milk although it426
has been revealed that the addition of prebiotics to cows’ milk based infant427
19
formulas can reduce these differences somewhat 77. The ability of prebiotics428
to modulate the infant gut microbiota in a manner similar to that associated429
with breastmilk will be discussed in greater depth later in this review.430
431
Thirty years ago, Stark and Lee pioneered the research into the influence of432
different approaches to feeding on the infant gut microbiota 54. This culture-433
based study paved the way for the more recent investigations and was434
notable in that it revealed that bifidobacteria levels varied greatly depending435
on feeding method, with breastfed infants having higher bifidobacteria levels436
compared to formula fed controls. Although it is now apparent that the feeding437
regime is not the sole determinant of the levels of bifidobacteria and438
lactobacilli in the infant gut 1, it is clear that feeding does have a crucial439
impact. The findings of this initial culture-based study by Stark and Lee 54,440
have been corroborated by several more recent culture-independent studies441
and reviews, which confirm that bifidobacteria are more dominant (and, in at442
least some cases, more diverse) in the gut of breastfed infants 57, 78-81. These443
studies have also revealed that E. coli and clostridia counts, including C.444
difficile, are lower in breastfed infants than those fed infant formula. Notably,445
when formula was supplemented with oligosaccharides it resulted in greater446
bifidobacteria counts in the faecal samples of the associated infants than was447
present in samples provided by the unsupplemented control group 57. Thus,448
in this case and as is often the case, the use of culture-independent449
techniques has resulted in the validation of earlier culture-dependent studies450
but has also significantly advanced our understanding of the broader451
consequences of feeding method choice with respect to the infant gut452
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microbiota. Thus, while culture-based approaches are rapid and relatively453
straight forward and therefore are useful as preliminary investigations, the454
more advanced techniques provide us with the greatest insight into the455
complex interaction between feeding method and gut microbiota.456
457
Other patterns have also been noted in that a review by Adlerberth and Wold458
(2009) noted trends towards higher levels of Lactobacillus rhamnosus in459
partially breastfed infants compared to weaned infants, observed that460
staphylococci are also more common in breastfed infants, while also461
establishing that higher levels of Klebsiella and Nitrobacteria are seen in462
formula fed infants 1. Fallani et al. have reported that Bacteroides were463
dominant in the gut microbial population of 6 week old formula fed infants 79464
and it has also been noted that the microbiota of formula fed infants is, in465
general, more diverse than that of their breastfed counterparts 78. Perhaps466
most notably of all, it has also been established that the consumption of467
breastmilk can significantly reduce the risk of necrotizing enterocolitis (NEC)468
(by 3-10 fold) in infants relative to those who are formula fed 82.469
470
In addition to the fact that the composition of milk consumed influences infant471
gut microbial composition, it has also been claimed that breastmilk contains472
microbes such as staphylococci, streptococci, lactobacilli, micrococci and473
bifidobacteria 83 and thus may be a direct source of the lactobacilli and474
bifidobacteria that become established in the infant gut 84, 85. These earlier475
studies have been supported by a 2010 study which provided further evidence476
of the role of breastmilk-associated microbes in the establishment of lactic477
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acid bacteria (LAB; which includes the lactobacilli) and bifidobacteria in the478
immature infant gut 86. In addition to the benefits of nutrients, oligosaccharides479
and, perhaps, microbes present in breastmilk on the infant gut microbiota, the480
antimicrobial impact of lactoferrin, as alluded to earlier, may be beneficial. In481
2009, a review found that oral treatment with lactoferrin reduced the incidence482
of sepsis and NEC in very low birth weight (VLBW) infants (usually including483
infants 1-1.5 kg in weight). Significant reductions in sepsis and NEC were484
apparent when lactoferrin was supplemented along with the probiotic L.485
rhamnosus GG 87.486
487
The introduction of solid foods (recommended by the European Society for488
Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) to occur489
not before 17 weeks of age and no later than 26 weeks) 88 is also known to490
induce alterations in the gut composition of infants 52, 89. Koenig and491
colleagues performed high-throughput sequencing of faecal DNA from one492
infant over a 2.5 year period 89. The study employed 454-pyrosequencing to493
generate 318,620 16S rRNA gene sequences from sixty samples and over494
500,000 metagenomic sequences from 12 samples. The study identified so495
called “steps” at which dramatic alterations occurred in the infant’s GIT496
microbiota which they found could be attributed to a significant life event 89.497
An example of this was “Step 3”, which took place around days 170-290,498
when the introduction of formula and peas to the diet of the previously499
exclusively breastfed infant resulted in a significant increase in Bacteroidetes.500
Overall, the study found that the introduction of solid foods was associated501
with an increase in Bacteroidetes and Firmicutes. It was also again suggested502
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that by 2.5 years the gut microbiota closely resembled that of an adult. The503
impact of weaning has also been investigated by others. In one case, this504
involved a study of 605 children from 5 European countries 90. The infants505
were examined 4 weeks after weaning commenced and were compared to the506
same infants prior to weaning, with results being generated using FISH and507
flow cytometry. The study found Bifidobacterium, the Clostridium coccoides508
group and Bacteroides to predominate after weaning but it was noted that the509
relative proportions of these were affected by the approach to pre-weaning510
feeding i.e. infants who had been breastfed had higher levels of bifidobacteria511
and decreased Bacteroides compared to infants who had been formula fed512
prior to weaning. The authors noted that despite weaning having a noticeable513
modifying effect on the gut microbiota of infants, other modulating factors such514
as mode of delivery, continued to exert measurable effects during the weaning515
period 90. Roger and colleagues have also reported an increase in the516
diversity of bifidobacteria corresponding to the introduction of solid foods 81.517
Finally, an alternative approach to the investigation of the impact of diet was518
demonstrated by De Filippo et al. in a study which compared diet, and its519
effects on the gut microbiota, of children (aged 1-6 years) from Europe (n=15)520
compared to those from rural Africa (n=14) 49. The African diet was low in fat521
and protein from animal sources and was high in fibre and starch and these522
children also differed in that they were breastfed up to 2 years of age. The523
authors performed pyrosequencing of the V5 and V6 hyper-variable regions of524
the bacterial 16S rRNA gene and generated 438,219 gene sequences,525
corresponding to 15,111 sequences per sample. The study found that the lack526
of diversity in the Western diet, and its over-reliance on nutrient dense,527
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processed and refined foods, appears to have an effect on the gut microbial528
composition. More specifically, the Western diet was associated with a529
reduced microbial diversity, with the European gut microbiota containing530
higher proportions of Firmicutes and Proteobacteria and lower proportions of531
Bacteroidetes and Actinobacteria 49.532
533
Despite the increased knowledge gained in recent years, it is clear that there534
is a need to more closely investigate the gut microbial composition of breast535
and formula fed infants as well as the effects of weaning and other diet-related536
issues. Investigations are also required to determine the duration of such537
effects and the short- and long-term impact that they have on infant health. It538
is anticipated that high-throughput sequencing technologies will provide539
significant clarity in this regard.540
541
Impact of family structure542
Though studied to a lesser extent, a factor that is emerging as a possible543
contributor to the composition of an infant’s gut microbiota is family structure.544
One relevant concept is known as the ‘sibling effect’ which is an adjunct to the545
hygiene hypothesis and postulates that allergic disease is lower in children546
from larger families 91. However, this theory remains controversial, particularly547
as the studies which have been performed to test this theory have been548
carried out in a myriad of different ways. Thus, to date, definitive evidence of549
the effects of family size, structure and birth order has yet to be established.550
Nonetheless, as part of the ALLERGYFLORA study 63, it was found (using551
culture-based approaches) that infants without older siblings had increased552
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proportions of non-E. coli enterobacteria as well as clostridia in the gut, but553
also had a lower anaerobe to facultative anaerobe ratio, resembling that of554
Caesarean delivered infants 63. In 2006, Penders et al. had reported the555
presence of greater bifidobacteria concentrations in infants with older siblings556
than those without. While family order and the environment have been557
implicated in allergic disease development 92, 93, the link between these effects558
and the composition of the intestinal microbiota requires further investigation.559
Further culture-independent studies are needed, for example, to identify if the560
gut microbiota of infants without older siblings is significantly different from561
that of other infants and if this predisposes them to later health risks. By562
providing answers to such questions, it will then become possible to address563
problems, that might previously have been overlooked, by positively564
influencing the gut microbiota (e.g. through probiotics use). As has been565
shown in the previous sections, the results of culture-based approaches are566
often verified by newer approaches, though these new technologies are567
advantageous as they provide a more detailed and less biased insight into568
such complex interactions between environmental factors and the gut569
microbiota of infants. Thus, there is an obvious opportunity to employ570
sequencing approaches to identify the gut microbiota of these infants and its571
relationship to health outcomes.572
573
Effect of maternal weight/diet574
The WHO released startling figures in 2010, which were updated in 2011,575
relating to the state of the world’s obesity crisis 94. The statistics showed that576
obesity levels have doubled since 1980 and that, as of 2008, 200 million men577
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and 300 million women were obese. Childhood obesity was also highlighted,578
with 43 million children under 5 years being obese in 2010. Surprisingly, 65%579
of the world’s populations now live in countries where more deaths occur due580
to obesity rather than being underweight 94. Obesity appears to be a vicious581
cycle, as an obese mother is more likely to have an obese infant, who in turn582
has an increased risk of becoming an obese adult 95. Work by Gordon, Cani583
and others have shown that obesity is influenced by the microbial composition584
of the gut 17, 48. The effects of childhood obesity on the composition of the585
child’s gut microbiota have recently been studied 96. This culture-independent586
study (comparing FISH and flow cytometry in combination, to results from587
microscopic detection and qRT-PCR) examined participants (n=25) and588
controls (n=24) at birth, at 3, 6, 12, 18 and 24 months and again when aged 4589
and 7 years (at which time BMI was calculated). The controls (i.e. normal590
weight children) were matched for birth mode, gestational age, probiotic591
treatment, breastfeeding duration, antibiotic treatment, atopic disease592
prevalence and cohort at age 7 years. Faecal samples were analysed and it593
was shown that children who were classified as being of normal weight had,594
and continued to have, higher levels of bifidobacteria than those who were, or595
who became, obese. They also noted lower Staphylococcus aureus levels in596
normal weight infants. This therefore provides a further indicator for the role of597
gut microbiota in obesity development and highlights the possibility of598
modulating disease risk through the alteration of the gut microbiota.599
600
A recent study has taken the alternative approach of investigating if a601
mother’s weight before or during pregnancy could impact on her infant’s gut602
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microbiota 24. The results from this 2010 study showed that infants of603
overweight mothers tended to be overweight or heavier at birth than those of604
normal weight mothers, while also revealing that overweight mothers had605
infants with decreased numbers of gut bacteria from the Bacteroides-606
Prevotella group at age 1 month, but had higher levels of Clostridium607
histolyticum in their gut at age 6 months. Similar results were observed among608
infants whose mothers underwent significant weight gain during pregnancy.609
The gut microbiota of the offspring of overweight mothers contained higher610
Clostridium leptum, lower Clostridium perfringens and higher S. aureus levels611
than that of the infants of normal weight mothers. In contrast, at 6 months612
bifidobacteria counts were higher in the infants of normal weight mothers than613
in those of overweight mothers. While this culture-independent study provides614
intriguing evidence of the effect that obese mothers have on their infant’s gut615
microbiota, research in this area still remains limited and additional culture-616
independent studies are required. There is an opportunity to apply high-617
throughput sequencing approaches to this area of research to compare the618
microbial profile of the mother at birth, and at later time points, with that of her619
infant and to track the changes in gut microbiota and the weight profile of620
both. There is a clear opportunity to exploit these technologies to considerably621
advance our knowledge of this complex interaction between gut microbiota622
and weight. Finally, it has also been shown that a mother can modulate her623
infant’s gut microbiota through the consumption of probiotics 97 or the use of624
antibiotics during pregnancy 98. The impact of probiotics and antibiotics on the625
infant’s gut microbial population will be addressed later in this review.626
627
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Probiotics628
The word probiotic is derived from the Latin “pro” meaning for and from the629
Greek “biotic” meaning living. Having undergone numerous alterations 99-101630
since the first proposed definition in 1965 102, today the most generally631
accepted, and most widely used definition, is that provided by the Food and632
Agricultural Organization (FAO) who define probiotics as “live microorganisms633
which, when consumed in adequate amounts as part of food, confer a health634
benefit on the host” 103. Additionally, criteria have been proposed to allow for a635
more systematic identification of probiotics and these have been outlined by a636
review in 2007 104. To date, representatives of the lactobacilli have been most637
extensively studied with a view to their use as probiotics 105.638
639
The issue of the health benefits associated with the consumption of a probiotic640
has been the focus of great attention in recent years. Since 2006, EFSA has641
implemented regulations pertaining to nutrition and health claims, including642
claims relating to probiotics. They have outlined that with respect to health643
claims relating to the ability of a probiotic to modulate the gut microbiota644
positively, they expect that the changes induced should have a specific health645
benefit, such as a reduction in specific (potentially) pathogenic646
microorganisms within the gut, which is clearly related to the consumption of647
the product under investigation 106. They do not, however, support the claim648
that increased levels of bifidobacteria or lactobacilli are beneficial to overall649
health per se, due to a lack of specific scientific evidence to support such a650
claim. Thus, in many cases, further evidence is needed to prove the role of651
specific probiotics strains in the gut and thus allow health claims relating to652
28
them. EFSA also require all scientific documents presented in the dossier653
supporting the health claim to specifically relate to the species and strain of654
probiotic microorganisms being examined. Thus, while there is considerable655
evidence supporting the role of some probiotics in gut microbiota modulation656
(as discussed below), care needs to be taken when making associated health657
claims.658
Given the recent EFSA rulings, it is not surprising that the specific659
mechanisms by which probiotics exert beneficial health effects on the host660
continues to be the focus of much attention 107-109. There are several proposed661
modes of action including the production of bacteriocins and other662
antimicrobials which inhibit other bacteria or the alteration of immune function,663
possibly through altered GALT function or through a physical enhancement of664
the mucosal barrier function 6. Indeed, the specific mechanism(s) involved will665
vary depending on the specific strain administered, further highlighting the666
importance of assessing each probiotic strain individually. Regardless of the667
precise mechanism(s) involved, a vast array of data exists relating to the668
beneficial impact of probiotics on host health 100, 105, 110. However, for the669
purpose of this review, the focus will be confined to the benefits to infant gut670
microbiota and subsequent health. With respect to healthy, full term infants,671
this review has previously outlined the transition that the infant gut undergoes672
from being initially sterile to having a composition that is relatively stable and673
resembles that of an adult by 2 years of age. It is during this initial transition674
phase that probiotics may be most beneficial. It is also notable, however, that675
in many cases the proposed benefit has related to increasing levels of676
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lactobacilli and bifidobacteria in the gut, which, as highlighted above, is not677
accepted as a health claim by EFSA.678
679
Given the ongoing debate regarding the significance of the ability of a680
probiotic to alter the composition of the gut microbiota (other than alterations681
in levels of specific pathogens), we have presented just a few examples to682
highlight the considerable degree to which some probiotics can bring about683
change. In one instance, a RCT examining the effects of supplementing the684
diet of infants with Bifidobacterium breve Bb12 for the first 28 days of life685
showed, using culturing techniques, that gut colonisation patterns were686
altered compared to those of infants in the placebo group 111. As one might687
expect, B. breve colonisation commenced more quickly in these infants but, in688
addition, after 6 weeks Lactobacilllus colonisation rapidly increased. In689
contrast, Enterobacteriaceae decreased over the supplementation period in690
treated infants compared to controls 111. Investigations have also taken place691
to determine if probiotic administration to pregnant mothers affects the gut692
microbiota of their infants. In 2006 a study investigated (using qPCR) the693
impact of probiotic administration of L. rhamnosus GG to pregnant mothers on694
the gut microbiota of their infants97. The probiotic was fed to 29 mothers 2-4695
weeks prior to delivery and up to 3 weeks after delivery, while the control696
group consisted of the infants of 24 mothers not in receipt of probiotics.697
Results showed that supplementation of the mother’s diet with the probiotic698
had a significant impact on the infants’ gut microbial composition, i.e.699
significantly increased bifidobacteria numbers and diversity in these infants at700
day 5 and a trend towards increased B. breve levels at age 3 weeks, relative701
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to the controls. Thus, probiotics have the potential to have a significant impact702
regardless of whether they are administered to the mother during pregnancy703
or directly to the infant, via supplemented formula after birth. A recent study704
was conducted using qPCR and flow cytometry coupled with FISH (FCM-705
FISH) to analyze the faecal microbiota of infants in Finland and Germany who706
received perinatal probiotic treatment 112. This study of over 150 infants found707
that the perinatal administration of probiotics did impact on the gut microbiota708
of the infants, but also found that the consequences depended on the feeding709
method employed (either breastfed or formula fed) as well as the microbiota710
present in the infant’s gut prior to probiotic administration. This area of711
research lends itself perfectly to further investigation through high-throughput712
sequencing, which will provide information with respect to the impact of these713
probiotics on gut microbes other than bifidobacteria and lactobacilli.714
715
In recent years there has been an increase in allergies and atopic diseases,716
which have paralleled a corresponding decrease in infectious diseases. In717
1976 John Gerrard first proposed the hygiene hypothesis 113, although it was718
not until 1989, when David P Strachen published his paper in the BMJ which719
focussed on hay fever, hygiene and household size that the hygiene720
hypothesis really began to gain scientific interest 91. Strachen’s paper721
suggested that decreased exposure to environmental challenges in early life,722
due to improved sanitation and hygiene practices, resulted in the reduced723
exposure of the immature immune system to the challenges necessary to724
develop tolerance and resistance to everyday environmental challenges e.g.725
dust, pollen etc. Additionally, in 1997, the hygiene hypothesis was extended to726
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incorporate the relationship between gut microbiota and immune regulation727
114. This hypothesis is still being debated and studied today. However, given728
the knowledge we have of the influential role that gut microorganisms play in729
the establishment, maturation and regulation of the infant immune system,730
studies have once more returned to the hygiene hypothesis to determine if731
alterations in the gut microbial composition could result in alterations in the732
development of the immune system, which result in an altered allergy risk. In733
2003, Bourlioux et al. reviewed the evidence up to that point which related to734
the role of the intestinal microbiota in immune function 115. The authors735
reminded us that alterations in the ratio of T helper 1/T helper 2 cells can have736
adverse consequences for the host i.e. increased Th2 levels result in an737
increased risk of allergy, while increased Th1 levels increases autoimmune738
disease risk e.g. diabetes mellitus. Studies have shown that having lower739
counts of bifidobacteria and atopy risk are associated and it has been740
proposed that bifidobacteria alter the level of Th2 development and inhibit the741
Th2 type response 116. Similarly, it has also been revealed that, in children742
with allergic parents, higher levels of lactobacilli in early life did reduce the risk743
of allergy development at age 5 years 117. It has also been suggested that the744
beneficial roles of specific commensal bacteria in allergic disease prevention745
may be due to alterations in the immune regulation process. The regulatory746
role that gut microbes play in the immune system has been convincingly747
demonstrated through studies involving gnotobiotic mice as well as human748
trials and, most recently, it was also shown to influence secretory IgA levels749
and subsequent allergic symptom development 4. Such a role of gut microbes750
in the regulation of the immune system would help explain why it is not only751
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Th2 mediated allergic diseases, but also Th1 associated illnesses such as752
Type 1 diabetes, which are increasing globally118.753
754
Following on from findings such as these, scientists have investigated the755
potential to favourably alter the infant gut microbiota in early life to decrease756
allergic disease risk. Notably, several studies have shown benefits in treating757
atopic children with probiotics and thus, modulation of the infant gut could758
potentially reduce the risk of them becoming allergic to environmental stimuli.759
The proposed regulatory role of gut microbes would occur predominantly760
during infancy and this may also explain why the effects of probiotics are more761
clearly observed in infants than in adults. This review will now summarise a762
number of relevant studies that address this topic.763
764
In a study published in 2002, L. rhamnosus GG was provided to pregnant765
women who had a family history of atopic diseases 119. The supplement was766
consumed for the last 4 weeks of pregnancy and throughout the breastfeeding767
period, until 3 months after the birth of the infant. The study found that the risk768
of the infant developing eczema was significantly reduced, i.e. 15% compared769
to 47% incidence in the control group up to 2 years of age. A subsequent770
study again involved supplementation with L. rhamnosus GG but, on this771
occasion, L. rhamnosus LC705 (DSM 7061), B. breve Bb99 (DSM 13692) and772
Propionibacterium freudenreichii ssp. shermanii JS (DSM 7076) were also773
provided to expectant mothers who had a family history of atopy 120. Once774
born, these infants also received this combination of probiotics, plus775
galactooligosaccharides (prebiotics). The authors found that compared to776
33
controls, probiotic treatment reduced the frequency of IgE associated (atopic)777
diseases, with an odds ratio (OR) of 0.71; 95% CI 0.5-1.00, though not778
significantly. Probiotic treatment did significantly reduced the risk of eczema779
with an OR of 0.74 CI 0.55-0.98, p<0.035. The authors also noted the780
frequent colonisation of bifidobacteria and lactobacilli in the gut of781
supplemented infants. In 2005, a study of 230 infants (aged 1.4-11.9 months)782
investigated the use of probiotics in the reduction in the symptoms of atopic783
eczema/dermatitis 121. Unlike the previous studies in which mothers received784
probiotics, this study specifically investigated the effect of directly treating the785
infants with probiotics. Treatment was either with Lactobacillus GG (LGG),786
LGG in combination with 3 other probiotics or a placebo. Participants were787
randomised into the 3 groups and treated for 4 weeks. Although the authors788
noted that symptoms improved, they did so in all three groups and only a non-789
significant improvement was observed when the probiotic treated group was790
compared with the control groups. The study found there to be potential for791
probiotics with respect to decreasing symptoms in IgE sensitised individuals792
but showed little benefit in non-IgE sensitised infants.793
794
Despite the fact that, as noted above, some positive outcomes have been795
reported, a 2007 review of this topic concluded that the studies to date are796
conflicting and inconclusive 122 and a Cochrane meta-analysis of the effects of797
probiotics in the treatment of eczema found no significant benefit of probiotic798
treatment 123. In a recent paper on this topic evidence of the benefits of799
providing probiotics in order to prevent atopic eczema was quite convincing.800
However, the authors did agree that weaker associations have been shown801
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between probiotics and other atopic diseases 124. The inconsistent findings to802
date most likely reflect differences with respect to the probiotic strains803
employed in the studies reviewed. It is apparent that large RCTs involving804
infants are needed to investigate fully and to specifically determine the805
benefits of treatment with specific probiotics in the context of allergy and806
atopic diseases. Use of high-throughput sequencing of faecal samples from807
affected versus unaffected individuals could be employed to determine if808
differences in symptoms are due to altered gut microbial compositions. Given809
that the hypothesis is that probiotic treatment alters gut microbiota, thus810
reducing allergy risk, one would presume that it is only a matter of time before811
culture-independent strategies are employed to investigate the link between812
probiotic use, alterations to the gut microbiota and subsequent impacts on813
allergy. It is also notable that the studies to date have often been limited to the814
use of lactobacilli as probiotics and thus the inclusion of other genera or the815
use of strains in combination may also be beneficial. While there has been a816
focus on the impact of specific strains, a consistent observation across many817
studies is the reduced microbial diversity in the gut of allergic infants 125. This818
reduction in diversity and allergic status relates well to the research on the819
association between early antibiotic exposure, the accompanying reduction in820
gut microbiota diversity and subsequent allergic disease risk 126, 127.821
822
While debate continues as to the specific beneficial health effects of many823
probiotics, one area where more convincing evidence exists is with respect to824
NEC. NEC, though first characterised over 100 years ago, still remains a825
poorly understood disease. The condition is characterised by abdominal826
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distension, bleeding of the intestines and ulcer formation 82, 128. There has827
been considerable interest in the use of probiotics to prevent NEC by828
normalising the intestinal microbiota of preterm infants, i.e. trying to change its829
composition to resemble that of healthy, full term infants 129, 130. Notably, trials830
using animal models of NEC have shown the benefits of introducing probiotic831
supplemented diets 131, 132. In one instance the animals, which were fed 109832
organisms/animal/day, had significantly reduced cases of NEC with just 7/24833
in the treatment group suffering from NEC, compared to 19/27 in the control834
group. Corresponding human studies have also been completed 133. In one835
case, the benefits of feeding Lactobacillus acidophilus in combination with B.836
infantis (no strain details provided) to infants was tested 134. This large, year837
long, study of over 1000 infants revealed that the cases of NEC, as well as the838
mortality rates in the treated group, were reduced compared to the controls. In839
2005, a trial was conducted to examine the effects of some probiotics and840
NEC prevention but in low birth weight infants 135. The study found that a841
reduction in NEC cases in treated infants occurred with a reduction in the842
incidence of NEC from 17% in controls to 4% in the treated group. They noted843
that levels of clinically significant NEC (classified as Bell Stage 2 or 3) in the844
treated group (1/72 i.e. 1%) were statistically significantly reduced compared845
to the control group (10/73 i.e. 14%). Several meta-analysis and systematic846
reviews have been conducted on this topic to date 136-138 and they have847
provided support for the use of probiotics in preterm infants to prevent NEC.848
Despite this, questions relating to what changes occur in the gut microbiota849
composition of NEC affected infants as well as the changes that occur850
following probiotic treatment remain unanswered and this is one knowledge851
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gap that lends itself to the utilization of modern DNA based approaches. It is852
anticipated that in the future, in addition to assessing the ability of different853
strains to prevent NEC, attention will also begin to focus on unravelling the854
specific mechanism(s) via which probiotics can prevent this disease.855
856
Some studies have also been carried out to investigate the potential benefits857
of using probiotics to prevent or treat antibiotic associated diarrhoea (AAD).858
The concept is that probiotics could temporarily colonise the gut, to859
compensate for the collateral damage to the gut microbiota resulting from860
antibiotic use, thus reducing the risk of diarrhoea due to altered digestion and861
absorption. It is estimated that between 8 and 30% of children suffer from862
AAD 139, 140. Two systematic reviews on this topic concluded that when863
probiotics and antibiotics were co-administered, AAD risk was reduced 141, 142.864
However, these reviews were based mainly on studies in adults. Cremonini865
and colleagues also highlighted the lack of RCTs, especially with respect to866
infants and noted that generalisations could not be made about probiotic867
effects, as different strains exerted different effects141. The studies which have868
taken place which relate to children have provided conflicting outcomes. In869
1990, a small study on children treated with L. acidophilus and Lactobacillus870
helveticus (administered prophylactically as Lactinex) found that they did not871
have a significant effect with respect to the prevention of AAD 143. In contrast872
in 2004, ESPGHAN concluded that there is promising evidence to suggest873
that some probiotics can contribute to the prevention of AAD 144. In a 2007874
review, it was concluded that (based on 6 RCTs at the time), co-treatment875
with probiotics did result in a reduced risk of AAD compared to those who876
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received antibiotics alone (28.5% to 11.9% reduction in risk) 116. This meta-877
analysis found that the most significant beneficial effects occurred when878
Lactobacillus GG, Saccharomyces boulardii and Bifidobacterium lactis and879
Streptococcus thermophilus were administered. They did not however, see880
any significant beneficial effect from administering Lactobacillus881
acidophilus/Bifidobacterium infantis or L. acidophilus/Lactobacillus bulgaricus.882
This again further emphasises the species and strain specific effects of883
probiotics and the need for rigorous testing of each proposed probiotic rather884
than making generalisations that all probiotics are beneficial to health. A885
recent Cochrane review on this topic, which also looked at the above886
mentioned species, again found evidence of a protective effect from887
concomitant treatment with probiotics during antibiotic therapy. However, once888
again the authors emphasised the species and strain specific effects that889
occurred and the need for further high quality studies on this topic before890
routine administration of probiotics to infants/children could be recommended.891
Thus, there is still a considerable gap in our knowledge in this area with892
respect to the specific impact of probiotic administration on the composition of893
the gut microbiota of infants in receipt of antibiotics. Further research is894
required to establish if temporary colonisation by probiotics occurs, to identify895
which microbial populations are impacted on by antibiotic administration and896
probiotic supplementation, to assess the duration of microbiota-related897
changes and to definitively establish the merits of probiotic administration in898
such circumstances. Finally, there is a strong need to carry out further studies899
to assess the success with which probiotics can prevent C. difficile associated900
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diarrhoea (CDAD) in infants and children. This was also the conclusion of a901
meta-analysis on this topic 145.902
903
Prebiotics904
In 1995, Gibson and Roberfroid defined a prebiotic as “a non digestible food905
ingredient that beneficially affects the host by selectively stimulating the906
growth and/or activity of one or a limited number of bacteria in the colon and907
thus improves health” 146. Based on this definition a substance must escape908
digestion or degradation in the stomach and small intestine and reach the909
colon intact, where it must only act as a stimulant for the growth of beneficial910
bacteria, which must then result in a measurable benefit to the host. The911
substances that have received the greatest attention to date have been912
oligosaccharides. Oligosaccharides are composed of repeating sugar units (2-913
20 units generally) and they exist naturally in breastmilk at a level of 10-12g/l914
147. It is notable however that the human milk oligosaccharides present in915
human breastmilk have yet to be produced commercially, and instead it has916
been fructooligosaccharides (FOS) and galactooligosaccharides (GOS) which917
have been the most studied as potential prebiotics. In the past, lactulose was918
investigated with a view to its use as a potential prebiotic, however such919
investigations have become more limited due to associated laxative effects at920
high doses. Although FOS and GOS are naturally present in foods such as921
bananas, celery, chicory and artichoke 77, the amount present is too small to922
be beneficial and thus there is considerable interest in incorporating prebiotics923
into functional foods following their extraction from plant sources or synthesis924
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thereof 148. This review will focus on the studies relating to the effect of925
prebiotics on infant health, through modulation of their gut microbiota.926
927
Oligosaccharides are unusual in that they consist of a β-glycosidic bond which928
is resistant to degradation in the human GIT, due to a lack of appropriate929
enzymes to digest this bond. They remain intact until they reach the colon930
where they are fermented by a subset of bacteria which are capable of931
degrading this bond. This fermentation results in short chain fatty acids,932
primarily acetate, butyrate and propionate. On the basis of culture-based933
studies, it has been known for quite some time now that the gut microbes934
which benefit from supplementation with prebiotics, such as bifidobacteria,935
proliferate at the expense of other gut microbes including Bacteroides,936
clostridia or coliforms, thus resulting in what is being suggested as being a937
more favourable gut microbial composition 149. Indeed, most research to date938
has focused on the ability of prebiotics to increase bifidobacteria and, to a939
lesser extent, lactobacilli numbers. However, it has been suggested that940
moving forward the increase in the numbers of other bacteria such as941
Roseburia and Eubacterium needs consideration also 150. Furthermore, as942
highlighted previously in this review, details on the actual benefit to health943
from increased levels of specific populations of microorganisms are needed944
i.e. simply targeting an increase in the numbers of specific microbes can not945
be employed as a health claim.946
947
Interest in prebiotics has increased as a consequence of evidence of several948
potential benefits, including the possibility of decreased colon cancer risk 151,949
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improved host resistance to pathogens, improved calcium absorption, altered950
blood lipids and altered immunological responses 152, 153, the majority of which951
still require further testing before EFSA will fully approve these claims.952
However extensive investigations have occurred and have been of953
considerable value 154. To date GOS and FOS have been the most954
extensively studied as prebiotics for supplementation to infant formula.955
ESPGHAN have concluded that the inclusion of 0.8g/100ml of oligosaccharide956
(combination of 90% oligogalactosyl-lactose and 10% high molecular weight957
oligofructosyl-saccharose) in infant formulas poses no major risk to the infant958
155. The review also showed evidence that 0.4g/dL, 0.8g/dL or 1g/dL mix of959
90:10 GOS:FOS ratio brought about a significant increase in faecal960
bifidobacteria levels. It appears that a combination of long chain and short961
chain FOS/GOS and the ratio they appear in plays an important role in the962
efficiency of the prebiotic and its ability to exert beneficial effects. Extensive963
studies have repeatedly shown that prebiotics increase bifidobacteria and964
lactobacilli levels 156, 157 and examples of these studies will be described965
below. Before proceeding, it should again be noted that lactobacilli and966
bifidobacteria constitute only a small proportion of the overall gut microbiota967
and future studies will need to investigate the global impact of prebiotics on968
the infant gut microbiota. Furthermore, as noted before, an increase in969
bifidobacteria and lactobacilli levels is not regarded as a valid health claim by970
EFSA.971
972
In 2008, a review of studies investigating the impact of prebiotics on infant973
health was completed 158. The authors highlighted the benefits of consuming974
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human milk oligosaccharides (HMOS) with respect to infant health. These975
included decreased incidence of gastroenteritis and respiratory infections 159.976
It was also noted that specific combinations of prebiotics, including short chain977
(sc) GOS/ long chain (lc) FOS, increased bifidobacteria and lactobacilli levels978
to the extent that, in some cases, levels of these genera were comparable to979
those observed in the gut of breastfed infants 104, 160-163. This impact was980
apparent despite the fact that these prebiotics had structures which differed981
from those of HMOS. In one such study qPCR and FISH were used in982
combination to identify and quantify the bifidobacteria in faecal samples from983
infants fed GOS and FOS supplemented feeds 161. This study revealed984
significant increases in faecal bifidobacteria in treated infants compared to985
controls and once again highlighted the ability of prebiotic supplemented986
formula to mimic breastfeeding effects on the gut microbiota, thus987
corroborating the results from earlier culture-based studies. As this review has988
shown, newer studies are now employing culture-independent methods (e.g.989
FISH and qPCR in combination or separately) to investigate more specifically990
the effects of prebiotics on the gut microbiota of infants, which may lead to991
greater insights compared to those provided by earlier culture-based992
approaches. There is also however, an opportunity to use sequencing993
technologies to more accurately assess the effects of prebiotics on the gut994
microbiota (and not just the effects on bifidobacteria and lactobacilli levels).995
996
Antibiotics997
While probiotics and prebiotics can potentially modulate the infant’s gut998
microbiota in a positive manner, antibiotics can exert a detrimental effect on999
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the infant’s commensal microbiota. The use of antibiotics has increased1000
dramatically and consequently the effects of specific antibiotics on the gut1001
microbiota of infants are a significant concern. A culture-based study in 19701002
was one of the first to examine the effects of various antimicrobials on the gut1003
microbial composition 164. The study suggested that the intestinal microbiota1004
was altered to different degrees depending on the spectrum of specificity of1005
the antimicrobial administered, the duration of treatment and the route of1006
administration. Interestingly in this early study, and also in some infant related1007
studies since, it has been shown that penicillin exerts a less significant effect1008
(and in some cases no significant effect) on the gut microbiota 165 relative to1009
other antibiotics, once more stressing the need to investigate the effect of the1010
different antimicrobials commonly prescribed during childhood in turn in order1011
to determine the specific impact that they have on the gut microbiota. Since1012
the initial Finegold et al. study highlighted the effects of antibiotics on the gut1013
microbiota, several other culture-based studies have also supported these1014
findings 165, 166. Following on from these culture-based approaches, culture-1015
independent approaches were completed and, in the majority of cases, they1016
corroborated the results of the earlier studies while also providing an even1017
greater insight 98. In 2009, a culture-independent study examining the effects1018
of antibiotics on the infant gut microbiota in the early postnatal period was1019
published 167. This study involved 26 infants, 5 of whom had been treated with1020
antibiotics. Faecal samples were analysed for the first 5 days of life and then1021
monthly for 2 months. The impact on the gut microbiota was assessed using1022
qPCR targeting the V1-V3 regions of the 16S rRNA gene. The study found1023
that antibiotic treated infants (treated with cefalexin 50mg/kg four times daily,1024
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for the first four days of life) had significantly lower bifidobacteria until 1 month1025
of age and had increased Enterococcus levels compared to antibiotic free1026
controls. The impact of antibiotic administration on colonisation patterns has1027
also been the subject of attention. In one instance this involved a study which1028
focussed on an infant in receipt of clavulanic acid and amoxicillin1029
(Augmentin®) for 13 days, followed by trimethoprim and sulfamethoxazol1030
(Bactrimel®) for 12 days 168. This study employed both culture-based and1031
culture-independent techniques to examine the effects of antibiotics on gut1032
microbial composition. The antibiotic treated infant had an extremely unstable1033
microbiota up to the age of 1 month, with E. coli being dominant in the early1034
colonisation period. However, the most significant difference between the1035
antibiotic treated infant and the controls was the apparent absence of gut1036
bifidobacteria. Indeed, up to 5 months of age no bifidobacteria were detected,1037
highlighting the prolonged effects of antibiotic treatment on some commensal1038
bacteria 168. Following on from the previously outlined negative effect of1039
antibiotic treatment on bifidobacteria populations, another study in 20101040
showed that treatment of infants with parenteral antibiotics (a combination of1041
ampicillin and gentamycin), administered within 48 hours of birth, reduced, but1042
did not completely eliminate bifidobacteria, i.e. some bifidobacteria such as B.1043
bifidum survived antibiotic treatment 169. At 8 weeks of age those who had1044
been treated with antibiotics continued to have a less diverse population of1045
bifidobacteria relative to controls. Recent reviews have indicated that the1046
recovery of microorganisms after antibiotic administration can be delayed 1261047
and that in some cases some bacteria (namely Bacteroides) may not re-1048
establish 57. In a recent longitudinal study of 28,354 mother-child pairs in the1049
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Danish national birth cohort it was found that antibiotics administered in the1050
first 6 months of life were positively associated with an increased obesity risk1051
in children of normal weight mothers by the time the children reached age 71052
170. Thus, the changes to the infant’s gut microbiota in the initial months of life1053
could predispose the infant to chronic illness in later life.1054
1055
The impact of administering antibiotics to expectant mothers with respect to1056
the gut microbiota and/or health of their infants has also been investigated 171.1057
Furthermore, in 2002, McKeever and colleagues examined the effect of1058
maternal antibiotic use on the risk of allergic disease in their infants 92. The1059
study was part of the general practice research database in the UK and1060
included 24,690 children. The authors noted that 3 or more exposures to1061
antibiotics during pregnancy was associated with an increased hazard ratio for1062
asthma (1.36; 95% CI 1.16-1.60), eczema (1.19; 95% CI 1.02-1.39) and hay1063
fever (1.33; 95% CI 1.0-1.77) in the infant. The positive association between1064
antibiotic use in the first year of the child’s life and subsequent asthma and1065
allergy risk was also demonstrated in a 2009 study, when it was established1066
among 193,412 children that such antibiotic use was associated with an1067
increased risk of asthma and allergies at age 6 or 7 172. Previous studies have1068
also supported this association between early life exposure to antibiotics and1069
increased asthma and allergy risk 173, 174. Russell and Murch have also1070
reviewed the impact of peripartum antibiotics on the gut microbiota of infants1071
and in turn, their health effects and have suggested that administration of1072
peripartum antibiotics could alter the initial colonisation of the infant gut,1073
resulting in an alteration to the GALT and a shift towards Th2 differentiation.1074
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Such a shift is known to result in an increased risk of atopy 175. Furthermore,1075
as highlighted previously in this review, changes to the gut microbiota in early1076
life could affect the regulation of the immune system, which in turn could1077
cause health effects. A complication in studying the effects of antibiotics and1078
atopic disease is called “reverse causation”. The concept is that antibiotics1079
may have preceded the atopic disease or may have been prescribed in1080
response to symptoms. Thus, it is difficult to separate these to identify cause1081
and effect.1082
1083
While these studies demonstrate the negative effects of antibiotics on the gut1084
microbiota, there is considerable merit in carrying out further investigations1085
using the newer technologies available to us. Thus, by not having to select for1086
specific microorganisms, as is the case when culture- or hybridisation-based1087
approaches are employed, one could generate an overall profile of the impact1088
of antibiotics on infant gut microbiota. While the studies to date are significant,1089
and it is notable that a recent meta-analysis of 18 studies also found a weak1090
positive association between antibiotic use in infancy and asthma and wheeze1091
risk (OR 1.27 95% CI 1.12-1.43) 176, there are a number of other studies, such1092
as that by Celedon et al. 177, that failed to reveal the existence of an1093
association. Similarly in 2007, the Koala Birth Cohort Study of over 2,7001094
families, once more failed to demonstrate any association between antibiotic1095
use and eczema or asthma risk 178. In contrast, the most recent publication on1096
this topic found that the limited diversity in the gut microbiota of infants arising1097
through antibiotic exposure before 1 month of age, was positively associated1098
with atopic eczema risk by the age of 2 years 179. This again provides support1099
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for the theory that it may be reductions in the diversity of the gut microbiota1100
(rather than in any particular species of bacteria) which results in an altered1101
development and regulation of the immune system and subsequently results1102
in long-term health consequences. Antibiotics by their very nature cause1103
alterations to the microbiota present in the individual. However, the extent of1104
the effects on beneficial microbiota, during and after the treatment period,1105
needs to be examined further. As a consequence of the research on the1106
concomitant use of probiotics and antibiotics and the observed benefits (such1107
as decreased antibiotic associated diarrhoea risk), the use of specific1108
probiotics in conjunction with antibiotics to benefit the host by minimising the1109
negative effects on gut microbiota composition, may become even more1110
prevalent in the future. New technologies such as high-throughput sequencing1111
will also improve our ability to more accurately study the gut microbiota of1112
antibiotic treated subjects in a less biased manner, than culture-dependent1113
techniques. In particular, the impact of antibiotics on the GIT of preterm1114
infants requires greater attention. Knowing the impact of different antibiotics1115
on fullterm and preterm infant’s gut microbiota acquisition and development1116
could lead to the selection of particular antibiotics on the basis of their1117
efficiency in dealing with the illness, while having a minimal impact on the1118
infant’s microbiota.1119
1120
Conclusions1121
The infant’s gut microbiota undergoes rapid and radical changes during the1122
first 2 years of life. During this period, changes at both the phylum and1123
species levels occur. The changes which occur are determined by the factors1124
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that have been outlined in this review. Some of the most influential factors1125
appear to be mode of delivery, feeding practices and the use of probiotics and1126
prebiotics to potentially modulate the infant gut in what appears to be a1127
positive manner (though there is a need for further research to determine what1128
constitutes a ‘normal healthy’ gut microbiota). However, in contrast, antibiotics1129
have clearly been shown to have detrimental and often prolonged effects.1130
Thus, the first 2 years of the infant’s life may pose a unique window of1131
opportunity, during which time the gut microbial composition can be positively1132
modulated through diet and lifestyle factors. However, a number of questions1133
remain. As scientists we must question what is the ideal composition of the1134
infant gut microbiota? Do we know what core gut microbes will lead to the1135
most favourable health outcomes? Does the core gut microbiome depend on1136
the age of the infant (i.e. should we have milestones of colonisation to aim1137
for), and should this change depending on other factors such as ethnicity?1138
Notably, breastmilk has been shown to be the optimum nutrition source for1139
infants, thus investigating the composition of the breastfed infant’s gut1140
microbiota at different time points may provide targets to aim for. If we know1141
the benefits of breastfeeding should we try to prolong these effects and mimic1142
them in the weaning period? While this review has outlined the significant1143
advances in our understanding of the acquisition and development of the1144
infant gut microbiota, it is evident that large knowledge gaps still exist. Most1145
notably we still struggle to define what constitutes a beneficial or normal gut1146
microbiota. In the future, additional research of the long-term impacts on1147
health arising from an altered infant gut microbiota and, of the duration of the1148
effects of different factors (such as breastfeeding or antibiotic use) on these1149
48
populations is needed. To date, high-throughput sequencing technologies1150
have been relatively under-utilized with respect to investigations of the infant1151
gut microbiota, despite their widespread use in other fields of microbial1152
ecology, or even the gut microbiota of adults. Where these technologies have1153
been utilized, in many cases the results correlate closely with those from1154
culture-based approaches, thus showing the ability to corroborate and1155
supplement the culture-based results with those generated using newer1156
technologies. Additionally, it is evident the significantly more comprehensive1157
insights that can be achieved by using the new technologies available.1158
Accordingly, it is anticipated that our movement into the metagenomic era will1159
provide us with detailed insights into the gut microbiota of infants, and the1160
factors which influence this microbiota, in the very near future. The value of1161
such research has the potential to be immense.1162
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Table 1: Techniques used to investigate the human gut microbiota; advantages, disadvantages and examples of use
Microflora associated
characteristics
Culture-dependent techniques Culture-independent
techniques
High-throughput sequencing
Technique
description
The use of characteristics
associated with microbes e.g.
SCFA production to identify if
differences exist in the gut
microbial populations between
different subject groups
Use of selective media to culture
specific microorganisms or
species of microorganisms e.g.
Man Rogosa Sharpe (MRS)
media for lactobacilli growth
Identify bacteria through
isolation and amplification of
bacterial DNA e.g. 16S rRNA
gene.
Includes: PCR, DGGE, TGGE,
qPCR, dot blot hybridization,
FISH, flow cytometry
Sequencing based
approaches used to rapidly
identify bacteria using bacterial
DNA as template e.g. 454,
Illumina, SoLID, Ion torrent
History of use In the past has been
predominantly used as an initial
population screen or in
epidemiological studies
Historically, the most frequently
used approach to identify
bacteria present in various
environments
Increasingly popular in past 2
decades with increasing
availability of computer based
technologies and software
programs
Became commercially
available at the beginning of
the 21st century and becoming
increasingly popular ever since
Advantages  Simple
 Inexpensive
 Suitable as initial
screen to test a
novel hypothesis
 Useful for large
population
screens e.g. in
epidemiology
studies
 Quick
 Inexpensive
 Limited skill
required
 Limited
equipment
needed
 Useful as the
initial screen
before more
detailed
investigations
 Relatively
inexpensive
 Relatively
simple
 More detailed
results
achievable
 Less biased
results
 Very detailed
information
 Bacterial
profile in
complex
environments
e.g. gut
microbiota can
be identified
 Huge
phylogenetic
information
provided
 Relatively
quick
Disadvantages  Provides limited
information
 No bacterial
 Up to 90% of
bacteria non-
culturable
 Prone to PCR
bias
 Requires
 Extremely
expensive
 Data handling
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species
identification
possible
 Provides limited
information
 Need prior
knowledge of
bacteria to
screen for
 Requires further
tests for species
identification
more
sophisticated
equipment
and training
on their use
 May need
several
methods in
combination to
get
appropriate
level of details
in results
requirements
are significant
 Requires
training on
sample
preparation
and machine
use and
experience of
interpreting
results
Examples of
studies
efficiently using
this technique
References 12, 14, 15 References 165, 180 Reference 90 References 2, 49
Future use
in infant gut
microbiota
research
Most likely to be used to test
novel hypotheses and to be
followed up with more detailed
techniques
Likely to become infrequently
used and to be mainly used in
combination with and verified by
newer technologies
Likely to remain popular in the
coming decade, but decrease
thereafter as increased
availability and use of
sequencing approaches
occurs
Increased use since 2000 as
cost is decreasing and likely to
become the main approach
used in the future
